Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
An article from
News roundup
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
Published July 24, 2026
Getty Images
Novo escalates Lilly false advertising suit with planned bid to halt comparative ads
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads
Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Pharma heavyweights clash over anti-obesity drug ads
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk is escalating its legal battle against Eli Lilly over its GLP-1 drug marketing, notifying a federal court that it…
Novo Nordisk sues Eli Lilly over misleading ads; Merck licenses alimatravir; AbbVie/Genmab clarify Epkinly trial; J&J touts…
The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly, accusing its arch-rival of…
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly…
Novo Nordisk said Eli Lilly's ads uses outdated research and leave out important information, which could mislead consumers.
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
